Bicycle Therapeutics PLC
BCYC6.440USD
-0.070-1.08%
收盤 11/07, 16:00（美東）報價延遲15分鐘
321.15M總市值
虧損本益比TTM
關於 Bicycle Therapeutics PLC 公司
Bicycle Therapeutics plc 是一家位於英國的臨牀階段生物製藥公司，正在開發一種新型藥物，稱爲 Bicycle 分子，用於治療現有療法無法治療的疾病。Bicycle 分子是完全合成的短肽，被小分子支架束縛，形成兩個環，以穩定其結構幾何形狀。該公司正在公司贊助的臨牀試驗中評估 BT8009，一種針對經過充分驗證的腫瘤抗原 Nectin-4 的 Bicycle 毒素結合物 (BTC)；BT5528，一種針對歷史上無法用藥的靶點 EphA2 的 BTC；以及 BT7480，一種針對 Nectin-4 和激動 CD137 的 Bicycle 腫瘤靶向免疫細胞激動劑 (Bicycle TICA)。此外，該公司正在開發用於放射性藥物的 Bicycle 放射性結合物 (BRC)，並通過各種合作伙伴關係，探索利用 Bicycle 技術開發腫瘤以外疾病的治療方法。其候選產品還包括 BT1718 和 BT7455。
Bicycle Therapeutics PLC簡介
公司代碼BCYC
公司名稱Bicycle Therapeutics PLC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
員工數量305
證券類型Depository Receipt
年結日May 23
公司地址Blocks A & B, Portway Building
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編CB21 6GS
電話11441223261503
網址https://www.bicycletherapeutics.com/
公司代碼BCYC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
Bicycle Therapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
--
--
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月7日 週五
更新時間: 11月7日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
21.80%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.57%
Invus Public Equities Advisors, LLC
4.03%
其他
56.08%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
21.80%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.57%
Invus Public Equities Advisors, LLC
4.03%
其他
56.08%
股東類型
持股股東
佔比
Hedge Fund
44.95%
Investment Advisor
17.67%
Investment Advisor/Hedge Fund
13.06%
Venture Capital
7.05%
Research Firm
4.43%
Individual Investor
1.59%
Family Office
0.25%
Pension Fund
0.24%
其他
10.75%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
261
44.53M
89.76%
-16.90M
2025Q2
261
46.21M
95.43%
-15.11M
2025Q1
263
46.04M
96.46%
-15.64M
2024Q4
263
44.84M
86.26%
-16.34M
2024Q3
260
44.49M
67.19%
-14.65M
2024Q2
252
44.12M
95.17%
-7.15M
2024Q1
268
34.84M
83.52%
-13.88M
2023Q4
272
34.95M
93.64%
-12.28M
2023Q3
272
41.70M
105.20%
-747.70K
2023Q2
255
34.13M
112.16%
-8.01M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
10.89M
21.83%
--
--
Jun 30, 2025
Forbion Capital Partners
3.45M
6.92%
--
--
Jun 30, 2025
Armistice Capital LLC
2.80M
5.61%
+128.00K
+4.79%
Jun 30, 2025
Westfield Capital Management Company, L.P.
2.78M
5.58%
+123.19K
+4.64%
Jun 30, 2025
Invus Public Equities Advisors, LLC
2.01M
4.04%
+200.00K
+11.03%
Jun 30, 2025
Point72 Asset Management, L.P.
1.77M
3.55%
-1.92M
-51.99%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.47M
2.94%
-68.19K
-4.44%
Jun 30, 2025
Millennium Management LLC
1.44M
2.89%
+990.19K
+218.38%
Jun 30, 2025
Candriam Luxembourg S.A.
1.32M
2.65%
--
--
Aug 31, 2025
Long Focus Capital Management LLC
1.32M
2.64%
+23.54K
+1.82%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Invesco NASDAQ Future Gen 200 ETF
0.51%
ALPS Medical Breakthroughs ETF
0.23%
Harbor Health Care ETF
0.22%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Health Innovation Active ETF
0.04%
SPDR S&P International Small Cap ETF
0.03%
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.64%
Invesco NASDAQ Future Gen 200 ETF
佔比0.51%
ALPS Medical Breakthroughs ETF
佔比0.23%
Harbor Health Care ETF
佔比0.22%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Health Innovation Active ETF
佔比0.04%
SPDR S&P International Small Cap ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
ActivePassive International Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
